Avelumab-cetuximab-radiotherapy (RT) versus standards of care (SoC) in locally advanced squamous cell carcinoma of the head and neck (SCCHN): Safety phase of the randomized trial GORTEC 2017-01 (REACH).

Yungan Tao,Anne Auperin,X.S. Sun,Christian Sire,Laurent Martin,G. Bera,Alexandre Coutte,J. Miroir,C. Lafond,Natacha Colin-Batailhou,Aline Maillard,Laurent Gibel,C Michel,J. Guigay,Jean Bourhis

Avelumab-cetuximab-radiotherapy (RT) versus standards of care (SoC) in locally advanced squamous cell carcinoma of the head and neck (SCCHN): Safety phase of the randomized trial GORTEC 2017-01 (REACH).

2018

Yungan Tao
Anne Auperin
X.S. Sun
Christian Sire
Laurent Martin
G. Bera
Alexandre Coutte
J. Miroir
C. Lafond
Natacha Colin-Batailhou
Aline Maillard
Laurent Gibel
C Michel
J. Guigay
Jean Bourhis

6076Background: Based on the hypothesis of a synergistic effect of the anti-PDL1 avelumab when combined with cetuximab (cetux) and RT, this new combination is tested in a large scale randomized tri...

Keywords:

Avelumab
Cetuximab
Carcinoma
Randomized controlled trial
Radiation therapy
Physical therapy
Medicine
Cancer research
head and neck
Oncology
Internal medicine
basal cell
locally advanced
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations